Three-Pronged attack on rare, deadly thyroid cancer shows promise before surgery
NCT ID NCT04675710
Summary
This study is testing a combination of three drugs given before surgery for a rare and aggressive form of thyroid cancer. The goal is to shrink the tumors, making them easier to remove completely and potentially improving survival. The trial is for patients whose cancer has a specific genetic change called BRAF V600E.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID GLAND ANAPLASTIC CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio, 44195, United States
-
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah, 84112, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic
Rochester, Minnesota, 55901, United States
-
Stanford School of Medicine
Stanford, California, 94304, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.